CN110522777A - A kind of antiepileptic action of Bupleurum chinense DC difference extract - Google Patents
A kind of antiepileptic action of Bupleurum chinense DC difference extract Download PDFInfo
- Publication number
- CN110522777A CN110522777A CN201910951034.1A CN201910951034A CN110522777A CN 110522777 A CN110522777 A CN 110522777A CN 201910951034 A CN201910951034 A CN 201910951034A CN 110522777 A CN110522777 A CN 110522777A
- Authority
- CN
- China
- Prior art keywords
- bupleurum
- volatile oil
- bupleurum chinense
- chinense
- chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000510654 Bupleurum chinense Species 0.000 title claims abstract description 65
- 230000003556 anti-epileptic effect Effects 0.000 title claims abstract description 30
- 239000000284 extract Substances 0.000 title claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 48
- 239000000341 volatile oil Substances 0.000 claims abstract description 46
- 241000202726 Bupleurum Species 0.000 claims abstract description 31
- 229940079593 drug Drugs 0.000 claims abstract description 27
- 239000000469 ethanolic extract Substances 0.000 claims abstract description 27
- 239000001961 anticonvulsive agent Substances 0.000 claims abstract description 20
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229960001848 lamotrigine Drugs 0.000 claims abstract description 17
- 238000002360 preparation method Methods 0.000 claims abstract description 14
- 238000000605 extraction Methods 0.000 claims abstract description 10
- 238000001256 steam distillation Methods 0.000 claims abstract description 8
- 206010015037 epilepsy Diseases 0.000 claims description 44
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- 239000000463 material Substances 0.000 claims description 5
- 230000002829 reductive effect Effects 0.000 claims description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims description 2
- 238000004821 distillation Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 26
- 150000001875 compounds Chemical class 0.000 abstract description 9
- 238000002474 experimental method Methods 0.000 abstract description 7
- 230000000144 pharmacologic effect Effects 0.000 abstract description 7
- 238000010992 reflux Methods 0.000 abstract description 4
- 239000002904 solvent Substances 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 19
- 239000000243 solution Substances 0.000 description 13
- 206010010904 Convulsion Diseases 0.000 description 11
- 230000036461 convulsion Effects 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 238000011160 research Methods 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 7
- 230000001037 epileptic effect Effects 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 238000011049 filling Methods 0.000 description 6
- 230000003285 pharmacodynamic effect Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 5
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- 229960005152 pentetrazol Drugs 0.000 description 5
- 206010009346 Clonus Diseases 0.000 description 4
- 208000005392 Spasm Diseases 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 4
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000002146 bilateral effect Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 210000003194 forelimb Anatomy 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 210000004295 hippocampal neuron Anatomy 0.000 description 3
- 210000001320 hippocampus Anatomy 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- VLSMHEGGTFMBBZ-OOZYFLPDSA-N kainic acid Chemical compound CC(=C)[C@H]1CN[C@H](C(O)=O)[C@H]1CC(O)=O VLSMHEGGTFMBBZ-OOZYFLPDSA-N 0.000 description 3
- 238000000520 microinjection Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 208000005809 status epilepticus Diseases 0.000 description 3
- 230000002123 temporal effect Effects 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000002877 Epileptic Syndromes Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- VLSMHEGGTFMBBZ-UHFFFAOYSA-N alpha-Kainic acid Natural products CC(=C)C1CNC(C(O)=O)C1CC(O)=O VLSMHEGGTFMBBZ-UHFFFAOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 239000008845 cholagoga Substances 0.000 description 2
- 229940124571 cholagogue Drugs 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 229950006874 kainic acid Drugs 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- LCPVQAHEFVXVKT-UHFFFAOYSA-N 2-(2,4-difluorophenoxy)pyridin-3-amine Chemical compound NC1=CC=CN=C1OC1=CC=C(F)C=C1F LCPVQAHEFVXVKT-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000756943 Codonopsis Species 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 208000001654 Drug Resistant Epilepsy Diseases 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 206010016228 Fasciitis Diseases 0.000 description 1
- 241001547125 Fritillaria thunbergii Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010059491 Intracranial haematoma Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241001522129 Pinellia Species 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 240000004980 Rheum officinale Species 0.000 description 1
- 235000008081 Rheum officinale Nutrition 0.000 description 1
- KYWSCMDFVARMPN-MSSMMRRTSA-N Saikosaponin A Chemical compound O([C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@]([C@H]3[C@]([C@@H]4[C@@]([C@@]5(C[C@H](O)[C@]67CO[C@]5([C@@H]6CC(C)(C)CC7)C=C4)C)(C)CC3)(C)CC2)(C)CO)O[C@@H]([C@@H]1O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O KYWSCMDFVARMPN-MSSMMRRTSA-N 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010046814 Uterine prolapse Diseases 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 240000008866 Ziziphus nummularia Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002082 anti-convulsion Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011705 epilepsy animal model Methods 0.000 description 1
- HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000001097 facial muscle Anatomy 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000009431 guipi Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229960004002 levetiracetam Drugs 0.000 description 1
- HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 229940090010 mysoline Drugs 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 210000002589 oculomotor nerve Anatomy 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 229940100692 oral suspension Drugs 0.000 description 1
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 description 1
- 229960001816 oxcarbazepine Drugs 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- DQMZLTXERSFNPB-UHFFFAOYSA-N primidone Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NCNC1=O DQMZLTXERSFNPB-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 201000010727 rectal prolapse Diseases 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- QLPRYZXNWYTFCI-UHFFFAOYSA-N saikosaponin D Natural products CC1OC(OC2CCC3(C)C(CCC4(C)C3C=CC56OCC7(CCC(C)(C)CC57)C(O)CC46C)C2(C)CO)C(O)C(O)C1OC8OC(CO)C(O)C(O)C8O QLPRYZXNWYTFCI-UHFFFAOYSA-N 0.000 description 1
- PQPVAGWUNWFCJE-UHFFFAOYSA-N saikosaponin a Natural products CC1OC(OC2CCC3(C)C(C2)C(C)(CO)CC4(C)C3C=CC56OCC7(CCC(C)(C)CC57)C(O)CC46C)C(O)C(OC8OC(CO)C(O)C(O)C8O)C1O PQPVAGWUNWFCJE-UHFFFAOYSA-N 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- CHQMHPLRPQMAMX-UHFFFAOYSA-L sodium persulfate Substances [Na+].[Na+].[O-]S(=O)(=O)OOS([O-])(=O)=O CHQMHPLRPQMAMX-UHFFFAOYSA-L 0.000 description 1
- FJPYVLNWWICYDW-UHFFFAOYSA-M sodium;5,5-diphenylimidazolidin-1-ide-2,4-dione Chemical compound [Na+].O=C1[N-]C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 FJPYVLNWWICYDW-UHFFFAOYSA-M 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000003478 temporal lobe Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 239000008767 xiaochaihu Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Neurology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to medicines, more particularly to a kind of medical usage of the antiepileptic action of Bupleurum chinense DC difference extract.By steam distillation and solvent refluxing extraction method, it is prepared for the volatile oil and ethanol extract of Bupleurum chinense DC.Pharmacological experiment shows that Bupleurum chinense DC difference extract all has apparent antiepileptic action, wherein suitable, volatile oil antiepileptic action is better than Bupleurum Chinese root to ethanol extract antiepileptic action with Bupleurum Chinese root.The antiepileptic efficacy that Bupleurum chinense DC volatile oil and Lamotrigine are used in combination is significantly better than the effect that mentioned component is applied alone, and be significantly better than radix bupleuri compound preparation and antiepileptic efficacy that Lamotrigine is used in combination, for Chinese and Western medicine compound preparation safety and quality controllable provide possibility.
Description
Technical field
The present invention relates to medicines, make more particularly to a kind of anti-epileptic of Bupleurum chinense DC difference extract
Medical usage.
Background technique
Epilepsy (Epilepsy) is very common one of the nervous system disease in the whole world, and most refractory nerveous system
One of disease of uniting, has sudden and repetitious pathological characteristic, and epileptic needs lifelong medication treatment mostly.Epilepsy be by
A kind of chronic cerebral functional disorder disease caused by many reasons, with temporary caused by the cerebral neuron over-discharge that repeated
When sexual centre nervous function it is not normal with the characteristics of, be main performance with jerk and the loss of consciousness.There are about 70,000,000 in the whole world
Epileptic, wherein 90% or more patient is located at low, middle income country.Epidemiological survey shows, the hair of China's epilepsy
Sick rate is 5 ‰~7 ‰, existing about 6,500,000~9,100,000 epileptic in the whole nation.The generation of epilepsy can not only cause health problem,
Make patient's holistic health low, intelligence and impaired body function, accident occur and injured risk is higher, and is adjoint insane
A series of social mentality's problems such as mood, family, the occupation that epilepsy generates, cause tremendous influence to the whole quality of life of patient.
In addition, the direct health care costs of epilepsy and because caused by quality of life and production work Disability indirect costs it is huge, make
At more heavy financial burden.Therefore, it understands the pathogenesis of epilepsy in depth, seek optimal therapeutic agent and control insane
The means of epilepsy all have important meaning to patient and society.
Different types of etiopathogenises can lead to epileptic attack, and pathogenesis is complicated, not yet illustrate completely so far.The treatment means of epilepsy
Including carrying out immunotherapy targeted autoantibody, drug therapy, surgical operation therapy and physical therapy etc., usual antiepileptic to the cause of disease
It (AEDs) is the preferred means for treating epilepsy, clinically common antiepileptic had both included that conventional antiepileptic drugs such as benzene bar compares
Appropriate, dilantin sodium, carbamazepine, sodium vedproate, Clonazepam, ethymal, mysoline etc., also include nearly 20 years both at home and abroad successively
Research and develop the new antiepileptic drugs of listing, such as Oxcarbazepine, Lamotrigine, Levetiracetam.But it is with dizziness headache, mutual aid
The side effects such as imbalance, allergic reaction, cause some patientss not to be resistant to.However, about 1/3 patient is in drug refractory, it is difficult
The property controlled epilepsy generally refers to reasonable application Canonical management 2 years or more (two or more different AEDs by AEDs
Use in conjunction and reach effective blood drug concentration), therapeutic effect is still bad, symptom control it is still undesirable, in order to control epilepsy hair
Make, operation just becomes another selection.Temporal epilepsy is most common one of epilepsy syndromes, about 50% in treatment of intractable epilepsy
It is all this type above.But medial temporal lobe structures (including inside structure) are complicated, before neighbouring thalamus, brain stem, arteria cerebri media, choroid
The important anatomy structures such as artery, oculomotor nerve, surgical procedure will cause serious complication accidentally, and the Capital University of Medical Sciences three wins brain
Hospital, section functional neurosurgery surgery is cut in the parallel temporal epilepsy stove of 436 patients with temporal epilepsies of in March, 2008 diagnosis and treatment in March, -2016
Except art, wherein 24 (5.5%) postoperative there are the complication such as hemiplegia, intracranial infection, intracranial hematoma, temporalis atrophy.And Chinese medicine is controlled
Treating epilepsy has Small side effects, multicomponent, multiple target point and the advantage for reducing epilepsy complication breaking-out, has attracted domestic and international scientific research
The concern of person has very wide development prospect.
Bupleurum Chinese root is the dry root of umbelliferae bupleurum (Bupleurum chinense DC.).Radix bupleuri is common solution
Medicine administered to bring out the cold is used as China's tradition conventional Chinese medicine, has the application in more than 2000 years.Radix bupleuri is listed in first recorded in Shennong's Herbal
Top grade, and be recorded to be summarised in and go through in version " Chinese Pharmacopoeia " and " dictionary of medicinal plant ".Have in inducing diaphoresis, it is soothing the liver, the effect of rising Yang,
Be usually used in cold, fever, fevers and chills alternate, malaria, liver depression and qi stagnation, chest and rib distending pain, rectal prolapse, uterine prolapse, irregular menstruation, it is anticonvulsion,
Anti-inflammatory, antidepression, anti-epileptic, antitumor etc..Modern pharmacology research shows that bupleurum Chinense volatile oil has antipyretic, anti-inflammatory, liver protection etc.
Effect.Saikoside is the main component of Bupleurum Chinese, and has extensive bioactivity, such as anti-inflammatory, antitumor, Hepatoprotective cholagogue,
Immunological regulation and central inhibitory action etc..Flavones ingredient in Bupleurum Chinese has the effects that cholagogue, antibacterial, sterilization.For
For Bupleurum Chinese treats the present Research of epilepsy, existing research at present shows that bupleurum total saponin, saikosaponin a, c, d, radix bupleuri are waved
(radix bupleuri Shugan Decoction, radix bupleuri Shugan Decoction joint guipi decoction add taste, radix bupleuri Shugan Decoction that fritillaria thunbergii is added to add taste plus taste bavin for hair oil and compound
Add Os Draconis Concha Ostreae soup etc., Xiao Chaihu Tang recklessly) there is certain effect to treatment epilepsy.Currently, mostly about by radix bupleuri compound preparation
The report being used in combination with common anti-epileptic Western medicine, significantly improves the curative effect of epilepsy after combination, and adverse reaction rate is bright
Aobvious to reduce, the trend of having become is used in combination in Chinese and Western medicine.
Bupleurum chinense DC records the function for all having promoting the circulation of qi according to " book on Chinese herbal medicine states hook member ", " book on Chinese herbal medicine brief points ", the Materia Medica
Effect；Supplement to Thousand Golden Prescriptions, " book on Chinese herbal medicine brief points ", that " Chinese medicine voluminous dictionary " record takes Aerial Parts of Bupleurum chinense DC juice drop ear to control soldier is deaf.Currently, right
The pharmacological research of Bupleurum chinense DC is more plain, only to antipyretic liver protection, anti-inflammatory, antiviral, analgesia and enhancing hair
The report of tubule function related fields, the report not being used in combination about Bupleurum chinense DC extract and anti-epileptic Western medicine more
Road.
Summary of the invention
The object of the present invention is to provide a kind of new drug activities of Bupleurum chinense DC difference extract, specifically
It says, the present invention provides a kind of Bupleurum chinense DC difference extracts and anti-epileptic Western medicine to be combined in terms of the drug of anti-epileptic
Application.
The present invention is achieved by the following technical solution:
On the one hand, the different extracts that the present invention provides a kind of Bupleurum chinense DC (are mentioned comprising volatile oil compositions, ethyl alcohol
Take component) purposes in epilepsy drugs is treated in preparation.
Preferably, the volatile oil of the Bupleurum chinense DC is made of following steps: weighing dry Bupleurum Chinese on the ground
Part simultaneously crushes, and is extracted by steam distillation, after being dried over anhydrous sodium sulfate to obtain the final product.
Preferably, use the extraction time of steam distillation for 12 hours, institute's water requirement is 5-10 times of medicinal material weight,
The drying time of anhydrous sodium sulfate is 12 hours.
Preferably, the Bupleurum chinense DC ethanol extract is made of following steps: with weighing dry Bupleurum Chinese
Upper part simultaneously crushes, and collects the dregs of a decoction after extraction by steam distillation volatile oil, and ethanol solution heating and refluxing extraction is added, and closes
And filtrate, it is concentrated under reduced pressure to give Bupleurum chinense DC ethanol extract.
Preferably, selection 70-95% ethanol solution, solid-liquid ratio 1:2-4, heating and refluxing extraction 3 times, every time 2 hours.
Preferably, the drug be using the volatile oil of Bupleurum chinense DC or ethanol extract as active constituent, in addition
The preparation that pharmaceutically acceptable auxiliary material or complementary ingredient are prepared.
Preferably, the preparation is tablet, capsule, granule, oral solution or suspension.
Preferably, the different extracts are active constituent.
Preferably, the different extracts include antiepileptic activity substance.
It can a second object of the present invention is to provide make full use of Bupleurum chinense DC resources of medicinal plant abundant
Energy.
Preferably, the 87.5% of the total biological yield of Bupleurum chinense DC biological yield Zhan (while being also that Bupleurum Chinese root is raw
7 times of produce amount).
Preferably, the content of Bupleurum chinense DC volatile oil is about 7.8 times of Bupleurum Chinese root.
It (include volatile oil compositions, second third object of the present invention is to provide the different extracts of Bupleurum chinense DC
Alcohol extracting component) it is used in combination with anti-epileptic Western medicine and treats the purposes in epilepsy drugs in preparation.
Preferably, anti-epileptic Western medicine is Lamotrigine.
Compared with prior art, the beneficial effects of the present invention are: pharmacological experiment is shown, Bupleurum chinense DC difference is mentioned
Take object that there is apparent antiepileptic action, wherein ethanol extract antiepileptic action suitable, volatile oil anti-epileptic with Bupleurum Chinese root
Effect is better than Bupleurum Chinese root, and the antiepileptic efficacy that Bupleurum chinense DC volatile oil and Lamotrigine are used in combination is significantly better than list
With the effect of mentioned component, and it is significantly better than the antiepileptic efficacy that radix bupleuri compound preparation and Lamotrigine are used in combination, is
The safety of compound Western medicine preparation and quality controllable provide possibility.
Specific embodiment
Below in conjunction with specific embodiment, the invention will be further described.It will be understood that following embodiment is merely to illustrate this
Invention is not for limiting the scope of the invention.
In the following examples, the experimental methods for specific conditions are not specified, usually according to normal condition or manufacturer provide item
Part carries out.
A kind of embodiment 1: preparation of Bupleurum chinense DC volatile oil and ethanol extract
Dry Bupleurum chinense DC 44.4kg is weighed, according to pharmacopeia (2015 editions) extraction by steam distillation 12h, nothing
Aqueous sodium persulfate dries 12h, merges, and claims oil weight 48.67g, calculating Bupleurum Chinese ground volatile oil yield is 0.1096%.The dregs of a decoction add
70-95%EtOH heating and refluxing extraction 3 times, each 2h, filtration merges, and is concentrated under reduced pressure to give the extraction of Bupleurum chinense DC ethyl alcohol
Object medicinal extract 6.06kg (paste-forming rate 13.65%).
Comparative example 1: the preparation of Cyclic nucleotide extract
Take radix bupleuri 12g, keel, ginger, Radix Codonopsis, ramulus cinnamomi, Poria cocos, radix scutellariae each 4.5g, tuber of pinellia 6g, rheum officinale 6g, oyster 4.5
Gram, it 6 pieces of jujube, after soaking in water half an hour, decocts 3 times, each 30min, filtering, merging filtrate, is concentrated under reduced pressure into medicinal extract, it is standby
With.
Effect example 1: influence of the Bupleurum chinense DC to Sombati epilepsy cell model
1.1 experimental material
The isolated primary hippocampal neurons cell from newborn SD rat bilateral hippocampus.Administration group is grouped situation such as table
Shown in 1.
1 Bupleurum Chinese of table is grouped situation to Sombati epilepsy cell model pharmacodynamic evaluation
1.2 experimental method
By isolated primary hippocampal neurons cell from newborn SD rat bilateral hippocampus with neuronal cultured solution
(Neurobasal-A, 2%B27,0.5mM GlutaMAX) is in 5%CO237 DEG C of constant incubators in carry out routine culture, with
5×105/ hole is inoculated into 6 orifice plates, after purity is identified in culture to 8d, is divided into 11 groups of (every group sets 6 multiple holes) such as table 2.Blank
Group is normally cultivated after being incubated for 3h with normal cell external solution, and model group cell is normally cultivated after giving no magnesium extracellular fluid stimulation 3h.
Other administration groups after being incubated for 3h with no magnesium extracellular fluid, are incubated for culture with the maintenance culture solution containing various concentration drug, use
Influence of the CCK-8 colorimetric determination each group to Sombati epilepsy cell survival rate.
1.3 experimental result
Table 2 is respectively grouped to Sombati epilepsy cell model pharmacodynamic evaluation result
CCK-8 testing result shows: blank group primary hippocampal neurons cell process thickening, and taper, triangle etc. is presented,
It is interweaved into network-like, cell space is plentiful, and halation is obvious.Compared to the blank group, model group degeneration atrophy is obvious, protrusion fracture,
Most neurons apoptosis.The hippocampal neural of Bupleurum chinense DC ethanol extract and the high and low administration group of volatile oil to damage
First cell has protective effect, wherein the high dose group of Bupleurum chinense DC ethanol extract and volatile oil and model group ratio
Compared with cell survival rate has significant difference (P < 0.05).Bupleurum chinense DC volatile oil, ethanol extract and radix bupleuri compound
It is substantially better than the effect that single medicine uses with the effect that Lamotrigine is used in combination, wherein Bupleurum chinense DC volatile oil and Rameau
The effect that triazine is used in combination is best.
1.4 synergy calculation methods and verifying
Based on above-mentioned experimental result, the present invention has also inquired into active component activity preferably part and the existing drug of radix bupleuri
Combination drug effect, in order to evaluate synergistic effect, the calculation formula that acted synergistically using Nintaus carries out relevant evaluation, specific method
Are as follows: q=PA+B/(PA+PB-PA×PB)。
P in formulaA、PBAnd PA+BRespectively A medicine group, B medicine group and two medicine combination group treatment rates.Q < 1 illustrates to produce after two medicines share
Raw antagonism；Q > 1 illustrates to generate synergistic effect after two medicines share, and q=1 illustrates to generate summation action after two medicines share.
Specifically, data as shown in table 2, the effective percentage of Bupleurum chinense DC volatile oil group (VAH group) are respectively
30.4%, the effective percentage of control drug Lamotrigine group (TLG) is 37.3%, Bupleurum chinense DC volatile oil+Lamotrigine
The effective percentage of group (VA+TLG group) is 84.6%, is computed, and q=1.51 > 1 illustrates Bupleurum chinense DC volatile oil and Rameau
Triazine combination has synergy.
Effect example 2: Bupleurum chinense DC causes the pharmacological research of epilepsy mouse model to pentylenetetrazole
2.1 experimental animals and drug
SPF grades of mouse of C57BL/6 male, random grouping such as table 1, every group 20, No Food or Drink by 12h before stomach-filling, normal to drink
Water.All stomach-filling drugs use 5 ‰ carboxymethylcellulose sodium solutions to prepare, blank group and model group intragastric administration on mice same volume
5 ‰ carboxymethylcellulose sodium solutions.
3 Bupleurum Chinese of table causes epilepsy mouse model pharmacodynamic evaluation to be grouped situation pentylenetetrazole
2.2 experimental method
All equal gastric infusion 7d of mouse, 1 time a day, the equal abdominal cavity in addition to blank group 60min after last time is administered
It injects pentylenetetrazole (60mg/kg), it is tetanic to observe and record mouse epilepsy outbreak rank, incubation period, duration of status convulsion, body immediately
Property spasm incidence and the death rate.
The classification of mouse epilepsy outbreak is using Racine standard: 0 grade: without convulsions；I grades: mouth, facial muscles clonic spasm；II grades: In
There is the rhythm and pace of moving things on the basis of I grades to nod；III level: there is forelimb clonic spasm on the basis of II grades；IV grades: after occurring on the basis of III level
Limb stretches；V grades: falling on the basis of IV grades.
2.3 experimental result
Respectively grouping causes epilepsy mouse model pharmacodynamic evaluation result to pentylenetetrazole to table 4
Note: compared with model group, P < 0.01 * P < 0.05, * *
Compared with blank group (CON) mouse, there is forelimb clonus and in various degree straight in model group (MOD) mouse
The symptoms such as vertical, tonic-clonic and tumble；Compared with model group, comparison medicine group (TLG), extract and comparison medicine combination group (EA+
TLG, VA+TLG, CHM+TLG) mouse epilepsy syndromes can be obviously improved, no IV grades or more symptom occurs, while can significantly extend
Mice convulsion incubation period, shorten duration of status convulsion (P < 0.05, EA+TLG), significantly reduce body tonic spasm incidence and
The death rate (P < 0.01), wherein VA+TLG group is substantially better than EA+TLG and CHM+TLG group.Bupleurum chinense DC ethanol extract
It can improve with volatile oil, Bupleurum Chinese root ethanol extract and volatile oil (in addition to Bupleurum Chinese root ethanol extract low dose group) small
Mouse tetanic spasm symptom, lengthening model mice convulsion incubation period shorten duration of status convulsion, reduce body tonic spasm and occur
Rate and the death rate (table 4).
Synthesis is as can be seen that Bupleurum chinense DC ethanol extract and Bupleurum chinense DC volatile oil all have obviously
Improve the pharmacological action that pentylenetetrazole causes epilepsy mouse model Status Epilepticus, and its ethanol extract antiepileptic action and Bupleurum Chinese root phase
When, volatile oil antiepileptic action is better than Bupleurum Chinese root.
The verifying of 2.4 synergies
Referring to above Section 1.4 of the calculation method, cooperateed with to associated with Bupleurum chinense DC volatile oil and Lamotrigine
Effect is verified.
Specifically, data as shown in table 4, (=1- is dead for the effective percentage of Bupleurum chinense DC volatile oil group (VAH group)
Die rate) it is respectively 45%, the effective percentage of control drug Lamotrigine group (TLG) is 50%, Bupleurum chinense DC volatile oil+drawing
The effective percentage of triazine group (VA+TLG group) is not 95%, is computed, and q=1.31 > 1 demonstrates Bupleurum chinense DC volatile oil
There is synergy with Lamotrigine combination.
The effect that Bupleurum chinense DC volatile oil and Lamotrigine are used in combination is substantially better than single medicine use and northern bavin
The effect that Hu aerial part ethanol extract or radix bupleuri compound and Lamotrigine are used in combination.
Effect example 3: the pharmacological research for the epileptic rat that Bupleurum chinense DC induces kainic acid (KA)
3.1 experimental animals and drug
SPF grades of rats of SD male, 220 ± 20g of weight, random grouping such as table 3, every group 20, all stomach-filling drugs are used
5 ‰ carboxymethylcellulose sodium solutions are prepared, and 5 ‰ sodium carboxymethylcelluloses of blank group and model group intragastric administration on mice same volume are molten
Liquid.
5 Bupleurum Chinese of table is grouped situation to the Epilepsy pharmacodynamic evaluation that KA is induced
3.2 experimental method
KA is established using the method for intracerebroventricular injection KA and causes epilepsy animal model.Rat with 10% chloraldurate (400mg/kg,
Intraperitoneal injection) after anesthesia, by overhead skin through iodine disinfection, after 75% alcohol takes off iodine, along head median line and two basal parts of the ear
The point of intersection of line starts to cut scalp, and notch is about 1-1.5cm, with the aponeurosis (aponeuroses) and outer membrane on cotton balls erasing skull, exposes
Rat head is fixed on rat stereotactic apparatus by bregma and coronal suture to position, and keeps head front and back in same level
On face.With stereotactic apparatus to be that label carries out telocoele positioning at bregma: 0.8mm after bregma, 1.6mm is opened on side, after positioning, is used
High speed cranial drill drills at positioning, in drill hole, using the micro-injection pipe knit stitch 3.8mm of customization, in micro-injection pump
The interior speed with 1 μ l/min of telocoele at the uniform velocity injects the KA solution that 3 μ l concentration are 0.5 μ g/ μ l to the right under promotion, and injection terminates
Let the acupuncture needle remain at a certain point afterwards 5min, then slowly screw out micro-injection pipe.After observing rat vital sign, scalp skin is sutured, mould is injected intraperitoneally
Observation to anesthetic effect in mouse cage is put into after element to disappear.
According to Racine grade scale, occurs IV grades or more breaking-out after modeling and be set to modeling success, not up to IV-V grades of hair
That makees is included into unsuccessful group of modeling and abandons；Modeling EEG of epileptic rats, which reaches V grades and is continued above 30min, then gives diazepam note
It penetrates liquid 2mg (10mg/kg) intramuscular injection and terminates breaking-out.Random grouping such as table 2 are carried out at mould rat.Start stomach-filling after 5d and gives drug
Treatment, 1 time a day, total 30d.Videograph rat behavior is used during experiment, IV grades or more of spontaneous seizure is included in
Data statistics records and analyzes its time of occurrence, number and severity.All stomach-filling drugs use 5 ‰ carboxymethyl celluloses
Sodium solution is prepared, 5 ‰ carboxymethylcellulose sodium solutions of blank group, sham-operation group and model group rats stomach-filling same volume.Administration
Each group rat broken end is taken brain and takes blood by 30d, and whole blood stands centrifuging and taking upper serum after 10min, and bilateral is separated in ice face
Cerebral hippocampus and cortex are all placed in -80 DEG C of refrigerators after materials and save backup.
3.3 experimental result
Table 6 is respectively grouped the Epilepsy pharmacodynamic evaluation result induced KA
Compared with blank group (CON) rat, there is IV-V grades of convulsibility generalized tonic-clonic in model group (MOD) rat
The symptoms such as breaking-out, the upright, tumble of forelimb clonus；Compared with model group, comparison medicine group (TLG) can be obviously improved epilepsy in rat disease
There is IV grades or more of severe epilepsy persistent state (Status Epilepticus, SE) in shape, only 1 rat, while can
It is significant to extend rat convulsions incubation period, shorten duration of status convulsion；Compared with model group, Bupleurum chinense DC ethanol extract
Epilepsy in rat symptom can be improved with volatile oil, Bupleurum Chinese root ethanol extract and volatile oil, reduced SE incidence (P < 0.05)
(table 6), while being able to extend rat model convulsions incubation period and shortening duration of status convulsion.
The verifying of 3.4 synergies
Referring to above Section 1.4 of the calculation method, cooperateed with to associated with Bupleurum chinense DC volatile oil and Lamotrigine
Effect is verified.
Specifically, data as shown in table 6, the effective percentage (=1-SE of Bupleurum chinense DC volatile oil group (VAH group)
Incidence) it is 40%, the effective percentage of control drug Lamotrigine group (TLG) is 50%, Bupleurum chinense DC volatile oil+Rameau
The effective percentage of triazine group (VA+TLG group) is 95%, is computed, q=1.36 > 1, demonstrate Bupleurum chinense DC volatile oil with
Lamotrigine combination has synergy.
In summary result of study can be seen that Bupleurum chinense DC ethanol extract and Bupleurum chinense DC volatilization
Oil all has the pharmacological action for improving the Epilepsy Status Epilepticus of kainic acid induction, and its ethanol extract anti-epileptic
Suitable, volatile oil antiepileptic action is better than Bupleurum Chinese root with Bupleurum Chinese root for effect.Bupleurum chinense DC volatile oil and Rameau three
The effect that piperazine is used in combination is substantially better than single medicine use and Bupleurum chinense DC ethanol extract or radix bupleuri compound and Rameau
The effect that triazine is used in combination.
The foregoing describe the preferred embodiment for the present invention, and however, it is not to limit the invention.Those skilled in the art couple
Embodiment disclosed herein can carry out the improvements and changes without departing from scope and spirit.
Claims (7)
1. purposes of the Bupleurum Chinese volatile oil in preparation treatment epilepsy drugs, which is characterized in that the volatile oil is for Bupleurum Chinese
The volatile oil of the volatile oil of upper part, the Bupleurum chinense DC is prepared as follows: weighing dry Bupleurum Chinese on the ground
Part simultaneously crushes, and is extracted by steam distillation, after being dried over anhydrous sodium sulfate to obtain the final product.
2. purposes according to claim 1, which is characterized in that use the extraction time of steam distillation for 12 hours,
Institute's water requirement is 5-10 times of medicinal material weight, and the drying time of anhydrous sodium sulfate is 12 hours.
3. purposes of the Bupleurum Chinese ethanol extract in preparation treatment epilepsy drugs, which is characterized in that the ethanol extract is
The ethanol extract of Bupleurum chinense DC, the Bupleurum chinense DC ethanol extract are prepared as follows: being weighed dry
Dry Bupleurum chinense DC and crushing, the dregs of a decoction of the collection after extraction by steam distillation volatile oil is added ethanol solution and adds
Circumfluence distillation, merging filtrate are concentrated under reduced pressure to give Bupleurum chinense DC ethanol extract.
4. purposes according to claim 3, which is characterized in that select 70-95% ethanol solution, solid-liquid ratio 1:2-4 adds
Circumfluence distillation 3 times, every time 2 hours.
5. the purposes in preparation treatment epilepsy drugs is used in combination in Bupleurum chinense DC extract and antiepileptic.
6. purposes according to claim 5, which is characterized in that the Bupleurum chinense DC extract is Bupleurum Chinese ground
Part ethanol extract or Bupleurum chinense DC volatile oil, the antiepileptic are Lamotrigine.
7. a kind of pharmaceutical composition for treating epilepsy, which is characterized in that the effective component of described pharmaceutical composition is Bupleurum Chinese
Upper part volatile oil and Lamotrigine, wherein the content of Bupleurum chinense DC volatile oil and Lamotrigine ratio is 8:1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910951034.1A CN110522777B (en) | 2019-10-08 | 2019-10-08 | Anti-epileptic effect of different extracts of aerial parts of bupleurum chinense |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910951034.1A CN110522777B (en) | 2019-10-08 | 2019-10-08 | Anti-epileptic effect of different extracts of aerial parts of bupleurum chinense |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110522777A true CN110522777A (en) | 2019-12-03 |
| CN110522777B CN110522777B (en) | 2021-09-14 |
Family
ID=68671356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910951034.1A Active CN110522777B (en) | 2019-10-08 | 2019-10-08 | Anti-epileptic effect of different extracts of aerial parts of bupleurum chinense |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110522777B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112336758A (en) * | 2020-11-05 | 2021-02-09 | 山西大学 | A bupleuri radix extract composition, and its preparation method and application in relieving convulsion |
| CN114588162A (en) * | 2022-03-30 | 2022-06-07 | 中国人民解放军空军军医大学 | Application of lamotrigine in treating autism tactile disorder |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1528759A (en) * | 2003-09-29 | 2004-09-15 | 江苏省中国科学院植物研究所 | Radix bupleuri stem-leaf extract and preparing method and use thereof |
| CN101062071A (en) * | 2007-06-18 | 2007-10-31 | 石任兵 | Total saponins from radix bupleuri extract and the preparing method thereof |
| CN107158056A (en) * | 2017-07-11 | 2017-09-15 | 十堰市太和医院 | A kind of preparation method of radix bupleuri suppository |
-
2019
- 2019-10-08 CN CN201910951034.1A patent/CN110522777B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1528759A (en) * | 2003-09-29 | 2004-09-15 | 江苏省中国科学院植物研究所 | Radix bupleuri stem-leaf extract and preparing method and use thereof |
| CN101062071A (en) * | 2007-06-18 | 2007-10-31 | 石任兵 | Total saponins from radix bupleuri extract and the preparing method thereof |
| CN107158056A (en) * | 2017-07-11 | 2017-09-15 | 十堰市太和医院 | A kind of preparation method of radix bupleuri suppository |
Non-Patent Citations (7)
| Title |
|---|
| BOCHUAN YUAN: "A systematic review of the active sailkosaponins and extracts isolated from Radix Bupleuri and their applications", 《PHARMACEUTICAL BIOLOGY》 * |
| 刘燕等: "柴胡三种萃取物的抗惊厥作用研究比较", 《中医药学报》 * |
| 刘玉法: "GC-MS 分析北柴胡地上部分的挥发油化学成分", 《北京中医药大学学报》 * |
| 张军臣: "槲皮素对颞叶癫痫大鼠学习记忆能力的影响", 《中华诊断学电子杂志》 * |
| 李春娜: "北柴胡化学成分及活性部位研究进展", 《中华中医药期刊》 * |
| 葛发欢: "《中药超临界二氧化碳萃取技术研究》", 31 March 2014 * |
| 马璇等: "北柴胡地上地下部位挥发油类成分的比较研究", 《海峡药学》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112336758A (en) * | 2020-11-05 | 2021-02-09 | 山西大学 | A bupleuri radix extract composition, and its preparation method and application in relieving convulsion |
| CN112336758B (en) * | 2020-11-05 | 2022-09-20 | 山西大学 | A bupleuri radix extract composition, and its preparation method and application in relieving convulsion |
| CN114588162A (en) * | 2022-03-30 | 2022-06-07 | 中国人民解放军空军军医大学 | Application of lamotrigine in treating autism tactile disorder |
| CN114588162B (en) * | 2022-03-30 | 2023-10-27 | 中国人民解放军空军军医大学 | Use of lamotrigine for the treatment of autism haptic abnormalities |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110522777B (en) | 2021-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105770373B (en) | A kind of Chinese medicine composition and its preparation method and application for treating children with high fever induced convulsions | |
| CN102178853B (en) | Chinese medicinal preparation for treating infantile epilepsia and preparation method thereof | |
| CN110522777A (en) | A kind of antiepileptic action of Bupleurum chinense DC difference extract | |
| CN101780227B (en) | Traditional Chinese medicine composition for treating acute stroke and preparation method thereof | |
| CN102357195B (en) | Medicinal composition for treating cardiovascular and cerebrovascular diseases, and preparation method and application thereof | |
| CN106309645A (en) | Pharmaceutical composition with anti-depression effect | |
| CN102512470B (en) | Pharmaceutical composition for treating cerebrovascular and cardiovascular diseases as well as preparation method and application | |
| CN101816712B (en) | Chinese medicinal composition for treating trigeminal neuralgia | |
| CN102145057A (en) | Antispasmodic traditional Chinese medicine composition and preparation method thereof | |
| CN102743734A (en) | Application of Tianlou Guizhi decoction in treatment of post-stroke spasm | |
| CN101190315A (en) | Traditional Chinese medicine composition for treating melancholia and preparation method thereof | |
| CN103920058A (en) | Traditional Chinese medicine preparation for treating headache and preparation method thereof | |
| CN101195003B (en) | Proprietary Chinese medicine for treating apoplexy and sequela | |
| CN100389780C (en) | Traditional Chinese medicine for treating depressive disorders, and its prepn. method | |
| CN101559139A (en) | Prescription of pure traditional Chinese medicine preparation for preventing and curing neurasthenia insomnia and preparation method thereof | |
| CN106474190A (en) | A kind of medicine for treating type Ⅱdiabetes mellitus and complication and preparation method thereof | |
| CN102406924B (en) | Medicine composition for treating cerebrovascular and cardiovascular diseases as well as preparation method and application thereof | |
| CN104383224A (en) | Drug for treating neurasthenia and preparation method of drug | |
| CN103349709B (en) | Traditional Chinese medicine preparation capable of tonifying qi and yin and nourishing liver and kidney | |
| CN104523861A (en) | Traditional Chinese medicine combination used for treating stroke and preparation method thereof | |
| CN104666874A (en) | Traditional Chinese medicinal capsule for treating tachyarrhythmia | |
| CN104324134A (en) | Traditional Chinese medicine composition for improving microcirculation and preparation method of traditional Chinese medicine composition | |
| CN102552423B (en) | Medicinal composition for treating migraine | |
| CN103705780A (en) | Medicament for treating intractable insomnia | |
| CN102973726A (en) | Chinese patent medicine for hypertension |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |